Retatrutide UK: The Triple Agonist Weight Loss Peptide

Retatrutide (also known by its development code LY3437943) is a novel peptide developed by Eli Lilly that simultaneously activates three hormone receptors — making it the world's first triple incretin receptor agonist to reach advanced clinical trials.

The three targets:

1. GLP-1 receptor (glucagon-like peptide-1): The same target as semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda). GLP-1 receptor activation reduces appetite, slows gastric emptying, improves insulin secretion, and has cardiovascular benefits.

2. GIP receptor (glucose-dependent insulinotropic polypeptide): The same additional target used by tirzepatide (Mounjaro). GIP receptor activation enhances insulin secretion, may improve fat metabolism, and appears to complement GLP-1 effects.

3. Glucagon receptor: This is what makes retatrutide unique. Glucagon receptor activation increases energy expenditure (thermogenesis), promotes fat oxidation (breakdown), reduces liver fat, and increases metabolic rate. This is the "third pillar" that may explain retatrutide's superior weight loss results.

The evolution of incretin therapy: - Generation 1: GLP-1 agonists (liraglutide, semaglutide) — single target — ~15% weight loss - Generation 2: Dual GIP/GLP-1 agonist (tirzepatide) — two targets — ~22% weight loss - Generation 3: Triple GIP/GLP-1/glucagon agonist (retatrutide) — three targets — ~24% weight loss

The addition of glucagon receptor agonism is theoretically elegant. Whilst GLP-1 and GIP reduce caloric intake through appetite suppression, glucagon increases caloric expenditure through enhanced thermogenesis. This dual approach — eating less AND burning more — may account for retatrutide's exceptional efficacy.

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with the dosing convenience established by semaglutide and tirzepatide.

The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, generated enormous excitement due to its remarkable weight loss results.

Trial design (NCT04881706): - 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity - Randomised to placebo or one of several retatrutide doses (1mg, 4mg, 8mg, or 12mg weekly) - Duration: 48 weeks - Primary endpoint: percentage change in body weight from baseline

Key results at 48 weeks:

• •Placebo: −2.1% body weight change
• •Retatrutide 1mg: −8.7%
• •Retatrutide 4mg: −17.1%
• •Retatrutide 8mg (slow escalation): −22.8%
• •Retatrutide 12mg: −24.2%

Categorical weight loss (12mg dose): - ≥5% weight loss: 100% of participants - ≥10% weight loss: 93% - ≥15% weight loss: 83% - ≥20% weight loss: 63% - ≥25% weight loss: 40%

These results are unprecedented. At the highest dose, participants lost an average of 24.2% of their body weight — equivalent to approximately 26 kg (57 lbs) for an average participant. The fact that 100% of participants on the 12mg dose lost at least 5% body weight suggests remarkably consistent efficacy.

Comparison to other treatments at similar timepoints: - Semaglutide 2.4mg (Wegovy): ~15% at 68 weeks - Tirzepatide 15mg (Mounjaro): ~22.5% at 72 weeks - Retatrutide 12mg: ~24.2% at 48 weeks

Notably, retatrutide achieved greater weight loss in a shorter timeframe (48 weeks) than tirzepatide did in 72 weeks, and the weight loss curves had not yet plateaued at 48 weeks, suggesting that longer treatment could yield even greater results.

Additional metabolic findings: - Significant reductions in liver fat (up to 86% reduction — potentially transformative for NAFLD/NASH) - Improved glycaemic control (HbA1c reductions comparable to dedicated diabetes treatments) - Reductions in triglycerides and other cardiovascular risk markers

The Phase 2 data provides initial safety signals, though the sample size is relatively small and the duration limited:

Gastrointestinal side effects (the most common): - Nausea: 16–46% (dose-dependent; highest at 12mg) - Diarrhoea: 14–26% - Vomiting: 6–18% - Constipation: 6–16% - Decreased appetite: 10–20%

These GI side effects were generally mild to moderate in severity, occurred primarily during dose escalation, and tended to resolve over time. The overall GI tolerability profile was comparable to tirzepatide.

Notable safety signals: - Heart rate increase: A small but measurable increase in resting heart rate (2–4 bpm) was observed, consistent with other GLP-1 agonists. This is generally considered clinically insignificant but requires monitoring. - Elevated lipase and amylase: Pancreatic enzyme elevations were observed, though no cases of clinical pancreatitis occurred in the trial. Enzyme elevations are a class effect of incretin therapies and do not necessarily indicate pancreatic disease. - Injection site reactions: Mild injection site reactions were reported at rates similar to other injectable peptide therapies.

What the Phase 2 data cannot tell us: - Rare adverse events (require larger Phase 3 populations to detect) - Long-term safety beyond 48 weeks - Cardiovascular outcomes (dedicated outcomes trials required) - Safety in specific populations (renal impairment, liver disease, elderly) - Drug interactions with common medications - Thyroid C-cell tumour risk (only detectable in long-term rodent studies)

The glucagon component — specific considerations: The glucagon receptor agonism introduces theoretical concerns not shared by GLP-1/GIP-only agonists: - Glucagon can increase blood glucose (counterbalanced by GLP-1 and GIP effects) - Glucagon promotes glycogenolysis (liver glycogen breakdown) and gluconeogenesis - Long-term effects of chronic glucagon receptor stimulation on the liver are unknown - Potential impact on ketone body production

Phase 3 trials with larger populations and longer durations will be essential for fully characterising the safety profile.

Eli Lilly has committed to an extensive Phase 3 development programme for retatrutide. Understanding the timeline helps set realistic expectations for UK availability.

Current Phase 3 programme (TRIUMPH trials): - TRIUMPH-1: Retatrutide in adults with obesity or overweight, without type 2 diabetes. Primary completion expected 2025–2026. - TRIUMPH-2: Retatrutide in adults with overweight or obesity and type 2 diabetes. Primary completion expected 2025–2026. - TRIUMPH-3: Long-term safety and efficacy extension study. - TRIUMPH-4: Cardiovascular outcomes trial (CVOT) — likely to run for several years.

Estimated regulatory timeline: - Phase 3 data readout: Late 2025 to mid-2026 (initial results) - FDA submission: Potentially late 2026 or 2027 - FDA approval (if granted): Potentially 2027–2028 - MHRA/UK approval: Typically follows FDA approval by 6–18 months - NICE appraisal: An additional 12–18 months after MHRA approval - Realistic UK NHS availability: 2029–2031

Why the timeline matters: - Retatrutide is not yet approved in any country - It cannot be legally prescribed in the UK until it receives MHRA marketing authorisation - NICE appraisal is required before NHS funding - Supply chain scale-up for a global launch takes significant time

Factors that could affect the timeline: - Positive Phase 3 results (on track) — could accelerate regulatory review - Breakthrough Therapy designation (if granted) — could expedite FDA review - Safety signals in Phase 3 — could delay or halt development - Manufacturing capacity — Eli Lilly is investing heavily in production facilities - Political and regulatory environment — weight loss medications are receiving increased regulatory attention

Private availability: Once MHRA approval is granted, retatrutide would likely be available through private prescriptions before NHS funding is confirmed through NICE appraisal. Based on the tirzepatide precedent, this gap could be 12–18 months.

A direct comparison of the three key weight loss peptides helps contextualise where retatrutide fits:

| Feature | Semaglutide (Wegovy) | Tirzepatide (Mounjaro) | Retatrutide | |---------|---------------------|----------------------|-------------| | Mechanism | GLP-1 agonist | GIP/GLP-1 agonist | GIP/GLP-1/glucagon agonist | | Max weight loss (trials) | ~15% | ~22.5% | ~24.2% | | Dosing | Once weekly | Once weekly | Once weekly | | Max dose | 2.4mg | 15mg | 12mg (Phase 2) | | UK approval status | Approved | Approved (diabetes); weight pending | Phase 3 trials | | Cardiovascular data | SELECT trial positive | SURPASS-CVOT ongoing | TRIUMPH CVOT planned | | GI side effects | Moderate-high | Moderate | Moderate | | Liver fat reduction | Moderate | Significant | Very significant (~86%) |

Key differentiators for retatrutide:

1. The glucagon effect: The addition of glucagon receptor agonism distinguishes retatrutide from all current competitors. This third mechanism increases energy expenditure — a fundamentally different approach to weight loss that complements appetite reduction.

2. Liver fat reduction: The Phase 2 data showing up to 86% reduction in liver fat is potentially transformative for patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). No current weight loss medication achieves comparable liver fat reduction.

3. Weight loss magnitude: Whilst the incremental improvement over tirzepatide (~24% vs ~22.5%) may seem modest, the shorter trial duration (48 vs 72 weeks) and the fact that the weight loss curve had not plateaued suggest the true maximum may be higher.

4. Metabolic versatility: Retatrutide's triple mechanism positions it not just as a weight loss drug but as a potential treatment for metabolic syndrome broadly — obesity, diabetes, NAFLD/NASH, dyslipidaemia, and potentially cardiovascular disease.

The critical unknown: Whether retatrutide's glucagon component introduces long-term risks not seen with GLP-1/GIP-only therapies. Phase 3 data will be essential to answering this question.

Retatrutide represents the next frontier in weight management pharmacotherapy, but for UK consumers, practical access remains years away. Here is what you need to know:

The realistic picture: - Retatrutide is not currently available in the UK through any legal route - It is not approved for human use in any country - Phase 3 trials are ongoing; results are expected from late 2025 - UK availability through private prescriptions is unlikely before 2028 at the earliest - NHS availability could be 2029–2031 or later

What to do now if you are interested: 1. Do not attempt to source "research-grade" retatrutide. Any product sold as retatrutide online is unregulated, unverified, and potentially dangerous. The compound is too new and too complex for the research chemical market to provide reliable quality. 2. Consider currently available options. Semaglutide (Wegovy) and tirzepatide (Mounjaro) are approved, well-studied, and available in the UK now. They offer substantial weight loss with established safety profiles. 3. Follow the clinical data. The Phase 3 TRIUMPH trials will provide the definitive data on retatrutide's efficacy and safety. These results will be published in major medical journals and widely reported. 4. Optimise your current approach. Whether or not you are using medication, the fundamentals of weight management — nutrition, physical activity, sleep, stress management — remain essential and should not be neglected whilst waiting for the "next best thing."

The broader significance: Retatrutide's Phase 2 results demonstrate that the field of obesity pharmacotherapy continues to advance rapidly. The progression from ~8% weight loss (liraglutide) to ~15% (semaglutide) to ~22% (tirzepatide) to ~24% (retatrutide) in under a decade is remarkable. Additional compounds in the pipeline — including oral formulations and even more potent multi-agonists — suggest further improvements are coming.

For UK consumers, this means better treatments are on the horizon. The challenge is patience — navigating the regulatory and funding processes that stand between promising clinical data and accessible, affordable treatment.

*This guide is for educational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional for personalised guidance on weight management.*